Veracyte, Inc. completed its acquisition of Convergent Genomics Inc. on 2026-09-14, according to the Form 8-K Veracyte, Inc. filed with the SEC on 2026-09-14. The filing states a price of $150 million.
| Acquirer | Veracyte, Inc. |
|---|---|
| Acquired | Convergent Genomics Inc. |
| Completed | 2026-09-14 |
| Price stated in the filing | $150 million |
| Reported by | Veracyte, Inc. (VCYT), the buyer |
| Filing | Form 8-K, filed 2026-09-14 |
Want the whole picture on Veracyte, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Veracyte, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Veracyte, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
1 cited source found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
What the filing says
On September 14, 2026, Veracyte completed its acquisition of Convergent pursuant to the terms of the Merger Agreement.
The price, in the filing's words
Under the terms of the Merger Agreement and in accordance with the terms set forth therein, at the effective time of the Merger, Veracyte paid to the securityholders of Convergent aggregate cash consideration of $150 million in cash, subject to customary purchase price adjustments for Convergent's cash, indebtedness, transaction expenses and net working capital.
More from the filing
Entry into a Material Definitive Agreement.
Merger Agreement On September 10, 2026, Veracyte, Inc., a Delaware corporation ("Veracyte"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Compass Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Veracyte ("Merger Sub"), Convergent Genomics Inc., a Delaware corporation ("Convergent"), and Shareholder Representative Services LLC, as the exclusive representative of the Securityholder Indemnifying Parties (as defined in the Merger Agreement) in connection with the transactions contemplated by the Merger Agreement.
Pursuant to the terms of the Merger Agreement, on September 14, 2026, Merger Sub merged with and into Convergent, whereupon the separate corporate existence of Merger Sub ceased and Convergent continued as the surviving corporation and a wholly owned subsidiary of Veracyte (the "Merger").
Quoted from Veracyte, Inc.'s Form 8-K.
This is the only completed acquisition Veracyte, Inc. reported under Item 2.01 in the last twelve months.
Who runs it now, who owns it, where the money comes from and what to watch for, every claim linked to its source.
Order Full Report on Veracyte, Inc.Look up Veracyte, Inc. and see what is on record before you decide.
Get the free SnapshotWhere this comes from
A public company must file a current report on Form 8-K with the SEC within four business days of completing a significant acquisition or disposition of assets, under Item 2.01 of the report. The acquired company sometimes files one too, when the deal makes it a subsidiary of the buyer.
Every fact on this page is taken from one of those filings and linked to it: which company acquired which, the date the filing gives for completion, and the price when the filing states one in dollars, shown next to the sentence that states it. A filing states what was bought and on what terms; it rarely states why, and neither does this page.